Xilio Therapeutics, Inc. XLO
8.68 USD +0.69 (+8.64%)
At closeNov 3, 2026, 4:00 PM EST
8.68 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
7.94 Day range 8.85
6.47 52-week range 12.01
- YTD
- -3.13%
- 1 year
- -27.06%
- Market cap
- 57.12M
- Revenue (ttm)
- 4.62M
- EPS (ttm)
- -0.60
- Shares out
- 43.96M
- Forward P/E
- -1.91
- YTD return
- -3.13%
- 1-year return
- -27.06%
- Volume
- 24.45K
- Avg volume
- 12.22K
- Open
- 8.03
- Previous close
- 7.99
- Day's range
- 7.94 – 8.85
- 52-week range
- 6.47 – 12.01
- Beta
- -0.20
- Analysts
- Buy
- Price target
- 4.50 (-48.2%)
- Earnings date
- Aug 8, 2024
YTD -0.73 (-7.76%)
Key statistics
- Enterprise value
- 3.42M
- PEG ratio
- 0.00
- Price / sales
- 10.56
- Price / book
- 2.33
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -3.04M
- Total cash
- 61.26M
- Total debt
- 8.41M
- Return on equity
- -170.96%
- Short % of float
- 0.48%
- 50-day average
- 1.01
- 200-day average
- 0.970715
Analyst view
Consensus: buy
Buy
Price target (mean) 4.50 -48.2% downside
Now 8.68
- Target (low)
- 4.00
- Target (mean)
- 4.50
- Target (high)
- 5.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.24.
Financials — quick view
XLO Revenue — quarterly 18.69M
XLO Net income — quarterly -6.37M
XLO EPS — quarterly -0.33
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.25 | -0.22 | +0.03 | +12.00% |
| Aug 8, 2024 | Jun 1, 2024 | -0.23 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -0.23 | -0.24 | -0.01 | -4.35% |
| May 14, 2024 | Mar 1, 2024 | -0.30 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.30 | -0.59 | -0.29 | -96.67% |
| Apr 1, 2024 | Dec 1, 2023 | -0.62 | -0.64 | -0.02 | -3.23% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 8, 2024 | Raymond James | main | Outperform | Outperform |
| May 30, 2023 | Chardan Capital | reit | Buy | Buy |
| May 11, 2023 | Chardan Capital | reit | — | Buy |
| Jan 27, 2023 | Morgan Stanley | main | — | Overweight |
| Dec 21, 2022 | Chardan Capital | init | — | Buy |
| Nov 10, 2022 | Raymond James | main | — | Outperform |
About Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- xiliotx.com
News
Xilio Therapeutics to Present at the Stifel 2026 Healthcare Conference 
Xilio Therapeutics Doses First Participant In Its Phase 1/2 Clinical Study Of XTX501 To Treat Metastatic Non-Small Cell Lung Cancer 
Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLC 
Raymond James Initiates Coverage On Xilio Therapeutics with Outperform Rating, Announces Price Target of $16 
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
Xilio Therapeutics Appoints Yariv J. Houvras, M.D. 
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates 
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
Your note
Sign in to keep a note on XLO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ATLAS VENTURE FUND XI L.P | Beneficial Owner of more than 10% of a Class of Security | Sale | Feb 7, 2024 | 0 |
| GILEAD SCIENCES INC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 17, 2024 | 9,105,450 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 10.39% | 4,566,817 | 5.07M | Sep 29, 2024 |
| Rock Springs Capital Management, LP | 6.83% | 3,003,259 | 3.33M | Sep 29, 2024 |
| Morgan Stanley | 3.46% | 1,522,102 | 1.69M | Sep 29, 2024 |
| Rivervest Venture Management LLC | 3.28% | 1,441,444 | 1.60M | Sep 29, 2024 |
| FMR, LLC | 3.18% | 1,395,853 | 1.55M | Sep 29, 2024 |
| Vanguard Group Inc | 2.05% | 902,531 | 1.00M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.68% | 739,563 | 820.91K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.42% | 182,832 | 202.94K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.36% | 160,024 | 177.63K | Sep 29, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.16% | 71,081 | 78.90K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.15% | 63,994 | 71.03K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.15% | 66,922 | 74.28K | Oct 30, 2024 |